Investor Unveils Deal Worth Up To £2.5M With Biotech Destiny
Venture capitalist group EMV said Monday that a subsidiary has entered into an asset purchase agreement to buy from Destiny Pharma Ltd. an antibacterial drug project in a transaction worth up to...To view the full article, register now.
Already a subscriber? Click here to view full article